Background: We previously proposed a formula to predict carboplatin clearance (CL) from four patient characteristics: plasma creatinine level, body weight, age, and sex (J Natl Cancer Inst 1995; 87: 573). Its accuracy was studied in a subpopulation of obese patients.
Introduction
We previously proposed a method to predict carboplatin clearance (CL) from four patient-specific variables (serum creatinine level (Scr), weight, age, and sex) accord- (with weight in kg, age in years, sex = 0 if male and sex = 1 if female, Scr in um) [1] . Van Wamerdam et al. [2] confirmed that the formula had no significant bias and was precise. However, according to the formula, predicted CL is mainly based on the patient ratio weight/ Scr. Therefore, there are grounds to suspect that the formula overpredicts the capacities of elimination of carboplatin in obese patients. Indeed, Scr is dependant on its renal elimination but also on its production which is determined as a function of patient muscle mass.
Thus, overweight due to an excess of body fat would not be associated with an increased Scr. This analysis was performed to evaluate the accuracy of our formula in a subpopulation of obese patients defined as those being overweight by more than 20%. The pharmacokinetic population program NONMEM was used to determine the best value of substitution for weight in the formula.
Patients and methods
Twenty-five adult patients (16 male and 9 female) received a one-hour i.v. infusion of carboplatin as part of established protocols for various tumor types. They ranged from 23 to 82 years old. Their weight ranged between 65 and 112 kg. They were 20% to 67% (median 36%) over the ideal weight which was calculated according to the Lorentz equation [3] : ideal weight (kg) = height -100 for male patients, and height -100 =-for female patients (with height in cm).
Their Scr, determined by enzymatic method using Ektachem slides (Eastman Kodak Co., Rochester, NY), ranged from 57 to 253 um (median: 98 um). Nine patients were included in the database used for the establishment of the formula [1] .
Pharmacokinetic study
Individual patients were studied in one cycle. Both sampling protocol and ultrafiltreable analysis were performed as previously described [1] , Briefly, samples were taken at the end of the infusion and 0.5-, 1-, 4-, 8-and 24-hour post-infusion. After immediate centrifugation at 4 °C, the plasma was separated and ultrafiltered through Amicon MPS1 micropartition system with YMT membranes at 4 C C for 20 min at 2000 g. Plasma ultrafilterable carboplatin levels were measured by flameless atomic absorption spectrophotometric analysis.
The actual CL was the fitted value obtained individually using the SIPHAR computer program (Simed, Creteil, France) according to a two-compartment open pharmacokinetic model with the weighting factor 1/yc.ic-' n order to determine the best value of substitution for weight in the formula, the computer program NONMEM [4] (version IV, level 1.1) was used. The regression model for CL (ml/min) was: with weight in kg, age in years, sex = 0 if male and sex = 1 if female, Scr in |im. A proportional error model was used for the residual and interpatient variabilities.
For each patient, the ability of the formula to predict the carboplatin CL values was assessed by calculating the percentage of error:
(calculated CL -actual CL) actual CL 100.
Results
Mean CL was 112 ml/min (ranges: 39 and 172 ml/min). By using the actual weight in the formula, CL was significantly overpredicted (Figure la) . The percentage of error ranged between -10% and +45% (median: + 10%) and was larger than +20% for seven patients. The final estimate (with 95% confidence intervals) of the regression coefficient provided by the NONMEM analysis was: 9 = 0.512 (0.373-0.651). Deletion of this coefficient was associated with a significant (P < 0.001) decrease in quality of fit which indicates that the mean value between ideal and actual weight [i.e., ideal weight + 0.512 • (actual weight -ideal weight)] was a better predictor than the ideal weight. The Figure lb shows the correlation between the CL calculated according to the formula from this mean value of weight and the actual CL. The percentage of error ranged from -21% to +22% (median: -8%).
Discussion
The substitution of actual body weight by the mean value between actual and ideal weight is associated with an impressive improvement in the adequacy between the predicted and the observed CL in obese patients. It is also interesting to note that using the ideal weight in the formula would lead to an underprediction of the CL. The same observation was done for estimation of the creatinine clearance from Scr: Sawyer et al. [5] showed that it was preferable to use the lean body weight overvalued by 20% of difference between actual and lean body weight than the lean body weight in the CockcroftGault equation [6] . This latter equation is often substituted for 51Cr EDTA-based glomerular filtration rate (GFR) in the Calvert formula [7] to predict carboplatin CL. Calvert et al. [8] showed that this approach results in a biased estimation of GFR. From the data of the 25 obese patients, we looked at the correlation between the predicted value using this approach and the actual weight (y) and the observed carboplatin CL (x): the relationship (y = 0.64 • x + 28 ml/min with r -0.73) was very similar to that between the clearance of 51Cr EDTA and creatinine clearance estimated by the Cockcroft-Gault equation obtained by Calvert et al. in 116 women and 73 men [8] . Therefore, the Calvert formula using the Cockcroft-Gault equation and actual weight will also result in biased results in obese patients and the degree of underprediction increases as their CL increases. In conclusion, although the weight correction we have derived has not been validated in a separate patient population, the formula we proposed [1] by using the mean value between the actual and ideal weights should constitute the best solution for estimating carboplatin CL in obese patients when 51Cr EDTAbased glomerular filtration rate determination was not possible.
